Results 101 to 110 of about 42,096 (271)

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

open access: yesAllergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter   +20 more
wiley   +1 more source

Prevalence of the Helicobacter pylori infection in chronic urticaria [PDF]

open access: yes
Background Urticaria is one of the most common clinically diagnosed dermatologic diseases. Wheals and pruritus are typical presentation of disease. Correlation between chronic urticaria (CU) and Helicobacter pylori infection has been proposed by many ...
رستمی مقدم, مجید
core  

Paths reunited: initiation of the classical and lectin pathways of complement activation [PDF]

open access: yes, 2010
Understanding the structural organisation and mode of action of the initiating complex of the classical pathway of complement activation (C1) has been a central goal in complement biology since its isolation almost 50 years ago.
Keeble, Anthony H.   +4 more
core   +1 more source

Angioedema [PDF]

open access: yesJAMA, 2018
James A, Tarbox   +2 more
openaire   +3 more sources

Successful Application of the Mast Cell Activation Test in Immediate Hypersensitivity to Amoxicillin

open access: yesAllergy, EarlyView.
This study included 28 amoxicillin‐allergic patients and 11 healthy exposed controls. Mast cells were differentiated from CD34+ progenitors over 8 weeks using cytokine cocktails. The mast cell activation test involved sensitization with patient or control sera and stimulation with free amoxicillin or G4/G5‐AXO dendrimers with successfully activated ...
Jose A. Céspedes   +11 more
wiley   +1 more source

Brazilian Guidelines for Hereditary Angioedema Management - 2017 Update Part 1: Definition, Classification and Diagnosis

open access: yesClinics, 2018
Hereditary angioedema is an autosomal dominant disease characterized by recurrent angioedema attacks with the involvement of multiple organs. The disease is unknown to many health professionals and is therefore underdiagnosed.
Pedro Giavina-Bianchi   +26 more
doaj   +1 more source

Unveiling Rare Genetic Variants in DAB2IP: New Insights Into the Pathogenesis of Recurrent Angioedema

open access: yes
Allergy, EarlyView.
Maurizio Margaglione   +8 more
wiley   +1 more source

Effect of Intramuscular Adrenaline on Histamine‐Induced Hypotension: A Randomised Placebo‐Controlled Pilot Trial

open access: yesAllergy, EarlyView.
Histamine infusions induce reproducible severe hypotension. Intramuscular adrenaline showed ‘supposedly therapeutic’ plasma concentrations but did not produce a sustained clinically relevant improvement in shock in the majority of recipients. These findings question adrenaline pharmacokinetic surrogate thresholds and support the need for faster and ...
Matthias Weiss‐Tessbach   +12 more
wiley   +1 more source

Institutional Incidence of Severe tPA-Induced Angioedema in Ischemic Cerebral Vascular Accidents

open access: yesCritical Care Research and Practice, 2018
Introduction. Tissue plasminogen activator (tPA) is commonly used in ischemic cerebral vascular accidents (CVAs). tPA is generally well tolerated; however, orolingual angioedema is a well-documented adverse effect. Angioedema is generally mild, transient,
Matthew Sczepanski, Paul Bozyk
doaj   +1 more source

Switching Long‐Term Prophylaxis to Donidalorsen for Hereditary Angioedema: 1‐Year OASISplus Results

open access: yesAllergy, EarlyView.
This study evaluated the long‐term safety and efficacy of donidalorsen in patients who switched from a long‐term prophylactic treatment (LTP) to donidalorsen with 1‐year outcomes. Patients who switched from LTP to donidalorsen experienced a 67.6% reduction in HAE attack rates over 52 weeks.
Marc A. Riedl   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy